Tarsus Pharmaceuticals (TARS) Assets Average (2020 - 2026)

Tarsus Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $571.6 million for Q1 2026.

• On a quarterly basis, Assets Average rose 30.25% year-over-year to $571.6 million in Q1 2026; TTM through Mar 2026 was $571.6 million, a 30.25% increase from a year earlier, with the FY2025 full-year figure at $469.6 million, up 46.18% from the prior year.
• Assets Average grew to $571.6 million in Q1 2026 per TARS's latest filing, from $548.4 million in the prior quarter.
• Across five years, Assets Average topped out at $571.6 million in Q1 2026 and bottomed at $180.2 million in Q1 2022.
• The 5-year median for Assets Average is $307.4 million (2024), against an average of $340.3 million.
• Across the five-year window, Assets Average dropped 7.87% in 2023 and jumped 81.47% in 2024, its largest moves.
• Year by year, Assets Average stood at $232.2 million in 2022, then increased by 14.97% to $266.9 million in 2023, then surged by 41.11% to $376.6 million in 2024, then surged by 45.59% to $548.4 million in 2025, then advanced by 4.25% to $571.6 million in 2026.
• Per Business Quant, the three latest TARS Assets Average figures stand at $571.6 million (Q1 2026), $548.4 million (Q4 2025), and $514.8 million (Q3 2025).